CLOs on the Move


 
Excerpted from the website: Chimerix discovers, develops and commercializes orally-available, antiviral therapeutics for a broad range of viral diseases, including cytomegalovirus, multi-drug resistant HIV infection and human papilomavirus.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.chimaerix.com
  • 2505 Meridian Pkwy Ste 340
    Durham, NC USA 27713
  • Phone: 919. 806.1074

Executives

Name Title Contact Details

Similar Companies

Remedi

Remedi SeniorCare is a United States-based institutional pharmacy business, serving a growing number of facilities extending from the Mid-Atlantic to the Midwest.

Rainier Therapeutics

Rainier is a uniquely diverse manufacturing company, producing a variety of display, shelter, fabric and shading products. Our mission is to create the highest quality available in everything we create--using the best technology and materials. Rainier consistently meets demanding requirements--and we`re at our best creating new solutions.

Oncology Pharma

Oncology Pharma, Inc. is a pioneering oncology company dedicated to licensing, developing, manufacturing and commercializing therapeutics. The company has assembled a team of executives and advisors with proven multi-disciplinary expertise in the field of oncology, therapeutics and leadership to identify, negotiate and amalgamate “best in class” research, technologies, therapeutics and delivery mechanisms that are synergistic and collaborative. The goal is to create value, reduce costs and increase the speed of regulatory approval and commercialization of effective and safer cancer drugs.

Santaris Pharma A/S USA

Santaris Pharma A/S USA is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cyteir

Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. The company is using its expertise in DNA damage response biology to advance a pipeline of novel drug candidates that selectively target key cancer vulnerabilities. Cyteir`s wholly owned lead compound, CYT-0851, is a potent and selective, oral investigational drug currently in a Phase 1/2 clinical trial for hematologic and solid tumors.